| 1. |
- Edén, Arvid, 1975, et al.
(författare)
-
Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients.
- 2010
-
Ingår i: AIDS research and human retroviruses. - : Mary Ann Liebert Inc. - 1931-8405 .- 0889-2229. ; 26:5, s. 533-40
-
Tidskriftsartikel (refereegranskat)abstract
- Initial viral decay rate may be useful when comparing the relative potency of antiretroviral regimens. Two hundred twenty-seven ART-naïve patients were randomized to receive efavirenz (EFV) (n = 74), lopinavir/ritonavir (LPV/r) (n = 77), or atazanavir/ritonavir (ATV/r) (n = 79) in combination with two NRTIs. The most frequently used NRTI combinations in the EFV and ATV/r groups were the nonthymidine analogues tenofovir and emtricitabine or lamivudine (70% and 68%, respectively) and, in the LPV/r group, lamivudine and the thymidine analogue zidovudine (89%). HIV-1 RNA was monitored during the first 28 days after treatment initiation. Phase 1 and 2 decay rate was estimated in a subset of 157 patients by RNA decrease from days 0 to 7, and days 14 to 28. One-way ANOVA and subsequent Tukey's post hoc tests were used for groupwise comparisons. Mean (95% CI) HIV-1 RNA reductions from days 0 to 28 were 2.59 (2.45-2.73), 2.42 (2.27-2.57), and 2.13 (2.01-2.25) log(10) copies/ml for the EFV-, LPV/r-, and ATV/r-based treatment groups, respectively, with a significantly larger decrease in the EFV-based group at all time points compared with ATV/r (p < 0.0001), and with LPV/r at days 7-21 (p < 0.0001-0.03). LPV/r gave a greater RNA decrease compared with ATV/r from day 14 (p = 0.02). Phase 1 decay rate was significantly higher in the EFV group compared with LPV/r (p = 0.003) or ATV/r (p < 0.0001). No difference was found in phase 2 decrease. EFV-based treatment gave a more rapid decline in HIV-1 RNA than did either of the boosted protease inhibitor-based regimens. The observed differences may reflect different inherent regimen potencies.
|
|
| 2. |
- Karlsson, Emma, et al.
(författare)
-
Different sources and degradation state of dissolved, particulate, and sedimentary organic matter along the Eurasian Arctic coastal margin
- 2016
-
Ingår i: Global Biogeochemical Cycles. - 0886-6236 .- 1944-9224. ; 30:6, s. 898-919
-
Tidskriftsartikel (refereegranskat)abstract
- Thawing Arctic permafrost causes massive fluvial and erosional releases of dissolved and particulate organic carbon (DOC and POC) to coastal waters. Here we investigate how different sources and degradation of remobilized terrestrial carbon may affect large-scale carbon cycling, by comparing molecular and dual-isotope composition of waterborne high molecular weight DOC (>1kD, aka colloidal OC), POC, and sedimentary OC (SOC) across the East Siberian Arctic Shelves. Lignin phenol fingerprints demonstrate a longitudinal trend in relative contribution of terrestrial sources to coastal OC. Wax lipids and cutins were not detected in colloidal organic carbon (COC), in contrast to POC and SOC, suggesting that different terrestrial carbon pools partition into different aquatic carrier phases. The C-14 signal suggests overwhelmingly contemporary sources for COC, while POC and SOC are dominated by old C from Ice Complex Deposit (ICD) permafrost. Monte Carlo source apportionment (C-13, C-14) constrained that COC was dominated by terrestrial OC from topsoil permafrost (65%) and marine plankton (25%) with smaller contribution ICD and other older permafrost stocks (9%). This distribution is likely a result of inherent compositional matrix differences, possibly driven by organomineral associations. Modern OC found suspended in the surface water may be more exposed to degradation, in contrast to older OC that preferentially settles to the seafloor where it may be degraded on a longer timescale. The different sources which partition into DOC, POC, and SOC appear to have vastly different fates along the Eurasian Arctic coastal margin and may possibly respond on different timescales to climate change.
|
|
| 3. |
- Zykov, Ilya Nikolaevich, et al.
(författare)
-
Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-beta-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model
- 2018
-
Ingår i: Antimicrobial Agents and Chemotherapy. - : AMER SOC MICROBIOLOGY. - 0066-4804 .- 1098-6596. ; 62:6
-
Tidskriftsartikel (refereegranskat)abstract
- Fosfomycin has become an attractive treatment alternative for urinary tract infections (UTIs) due to increasing multidrug resistance (MDR) in Escherichia coli. In this study, we evaluated the pharmacokinetic (PK) and pharmacodynamic (PD) indices of fosfomycin and its in vivo activity in an experimental murine model of ascending UTI. Subcutaneous administration of fosfomycin showed that the mean peak plasma concentrations of fosfomycin were 36, 280, and 750 mg/liter following administration of a single dose of 0.75, 7.5, and 30 mg/mouse, respectively, with an elimination half-life of 28 min, and urine peak concentrations of 1,100, 33,400, and 70,000 mg/liter expected to be sustained above 1 mg/liter (MIC of the test strain, NU14) for 5, 8, and 9.5 h, respectively. The optimal PK/PD indices for reducing urine colony counts (number of CFU per milliliter) were determined to be the area under the concentration-time curve/MIC from 0 to 72 h and the maximum concentration/MIC on the basis of the dose-dependent bloodstream PK and the results of an evaluation of six dosing regimens. With a dosing regimen of 15 mg/mouse twice (every 36 h), fosfomycin significantly reduced the number of CFU per milliliter of all susceptible strains in urine, including clinical MDR strains, except for one clinical strain (P = 0.062). Variable degrees of reduction were observed in the bladder and kidneys. No significant reductions in the number of CFU per milliliter were observed with the resistant strains. In conclusion, fosfomycin shows concentration-dependent in vivo activity, and the results suggest that fosfomycin is an effective alternative to carbapenems in treating MDR E. coli in uncomplicated UTIs. The data on the effectiveness of fosfomycin against the MDR isolates along with the results of PK/PD modeling should facilitate the further development of improved recommendations for its clinical use.
|
|
